Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Ginkgo’s financial condition, capital markets activity, governance developments, and material events related to its biological product manufacturing and cell engineering platform.
Recent DNA SEC filings include multiple Forms 8-K. These current reports cover topics such as quarterly financial results, entry into a Sales Agreement for potential at-the-market offerings of Class A common stock, and corporate governance matters, including changes in executive responsibilities and the preliminary approval of a settlement of stockholder derivative actions. Each 8-K also confirms that Ginkgo’s Class A common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol DNA.
Investors reviewing Ginkgo Bioworks’ filings can use this page to locate quarterly earnings press releases furnished on Form 8-K, agreements related to equity issuance, and descriptions of legal or governance developments. Over time, the broader filing history may also include annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements that discuss topics such as business segments, risk factors, and corporate governance practices.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly see the main themes, then drill into the original forms for details about Ginkgo Bioworks’ cell engineering and biosecurity activities, capital structure, and other disclosed matters.
Ginkgo Bioworks Holdings, Inc. (DNA) has filed a Form 144 indicating a proposed sale of 2,200 Class A shares through Fidelity Brokerage Services, valued at $24,596, with an expected trade date of 07/09/2025 on the NYSE. The filing states that 46,344,630 shares are outstanding, meaning the contemplated sale represents roughly 0.005 % of the public float—well below the Rule 144 limit of 1 % or the average-daily-volume test.
The “Securities Sold During the Past 3 Months” table lists Austin Che as having executed 52 separate transactions of 99 shares each, totaling 5,148 shares between 04/09/2025 and 06/23/2025. No aggregate proceeds figure is supplied, but individual sales ranged from $567 to $941 per lot. The upcoming 2,200-share sale therefore continues a pattern of small, periodic dispositions.
No financial results, operational updates, or corporate events are disclosed in this notice. From a capital-markets perspective, the filing merely provides advance disclosure of a minor insider sale and does not alter the company’s fundamentals or capital structure.
Form 144 Notice of Proposed Sale filed by Austin Che of Ginkgo Bioworks Holdings (NYSE: DNA) indicates planned sale of 99 Class A shares with an aggregate market value of $834.57, to be executed through Fidelity Brokerage Services around June 23, 2025.
The shares were originally acquired on October 12, 2022, through restricted stock vesting as compensation. The filing reveals extensive recent trading activity by the seller, with systematic sales of 99 shares per transaction over the past three months (March-June 2025), totaling 57 transactions.
Notable trading patterns show:
- Share prices ranging from $5.15 to $9.51 per share
- Consistent selling volume of 99 shares per trade
- Recent price appreciation trend in June 2025, with transactions reaching $8-9 per share
- Total outstanding shares: 46,344,630
Form 144 filing for Ginkgo Bioworks Holdings details proposed sale of securities by insider Austin Che. Key details:
- Proposed sale of 99 Class A shares through Fidelity Brokerage Services, with aggregate market value of $857.34
- Shares were acquired on October 12, 2022 through restricted stock vesting as compensation
- Extensive trading history shows consistent sales of 99 shares per transaction from March-June 2025
- Sale prices have ranged from $5.16 to $9.51 per share over the past 3 months
- Total shares outstanding: 46,344,630
The planned sale represents a continuation of a systematic selling pattern, with the insider executing regular small-volume transactions. Recent trading shows increasing share prices, with June 2025 transactions averaging higher values than earlier months.